Advertisement

Topics

Eli Lilly’s Cyramza Approved for HCC Patients, Boxed Warning Label Removed by FDA

20:00 EDT 12 May 2019 | BioSpace

The drug was approved as a second-line treatment for HCC patients who have an alpha-fetoprotein biomarker.

Original Article: Eli Lilly’s Cyramza Approved for HCC Patients, Boxed Warning Label Removed by FDA

NEXT ARTICLE

More From BioPortfolio on "Eli Lilly’s Cyramza Approved for HCC Patients, Boxed Warning Label Removed by FDA"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...